Drug Smackdown: Amgen vs. Eli Lilly miscellaneous Fool Interleukin-17 inhibitors from Amgen (Nasdaq: AMGN ) and Eli Lilly (NYSE: LLY ) were both tested in patients with moderate to severe speckle psoriasis . Here's type A table looking at the efficacy data for the most effective dose for each drug. Eli Lilly Phase II psoriasis examination meets primary endpoint medicine Business Review all iii news articles » Link To Article
No comments:
Post a Comment